Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wright

Showing results (371-380 of 617) with videos related to

Pageof 62
Sort By:
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
Biology of Sex Differences|May 8, 2019
Sex differences in negative affect and postoperative pain in patients undergoing total knee arthroplastyMeghna Nandi, Kristin L Schreiber, Marc O Martel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.
British Journal of Haematology|August 3, 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?John Gerecitano, Andre Goy, John Wright, et al.
BMJ Open|June 30, 2022
Vulnerabilities in child well-being among primary school children: a cross-sectional study in Bradford, UKKate E Pickett, Mildred Ajebon, Bo Hou, et al.
Cancer Medicine|January 24, 2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancerJohn Arcaroli, Kevin Quackenbush, Arvind Dasari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancerHelen Mackay, David Hedley, Pierre Major, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group studyTerzah M Horton, Debananda Pati, Sharon E Plon, et al.
Archives of Pathology & Laboratory Medicine|December 1, 2018
Data Set for the Reporting of Malignant Odontogenic Tumors: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer ReportingPieter J Slootweg, Edward W Odell, Daniel Baumhoer, et al.
Wellcome Open Research|June 14, 2024
COVID-19 vaccine hesitancy in an ethnically diverse community: descriptive findings from the Born in Bradford studyJosie Dickerson, Bridget Lockyer, Rachael H Moss, et al.
Pageof 62

Showing results (371-380 of 617) with videos related to

Sort By:
Pageof 62
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
Biology of Sex Differences|May 8, 2019
Sex differences in negative affect and postoperative pain in patients undergoing total knee arthroplastyMeghna Nandi, Kristin L Schreiber, Marc O Martel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.
British Journal of Haematology|August 3, 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?John Gerecitano, Andre Goy, John Wright, et al.
BMJ Open|June 30, 2022
Vulnerabilities in child well-being among primary school children: a cross-sectional study in Bradford, UKKate E Pickett, Mildred Ajebon, Bo Hou, et al.
Cancer Medicine|January 24, 2013
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancerJohn Arcaroli, Kevin Quackenbush, Arvind Dasari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancerHelen Mackay, David Hedley, Pierre Major, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group studyTerzah M Horton, Debananda Pati, Sharon E Plon, et al.
Archives of Pathology & Laboratory Medicine|December 1, 2018
Data Set for the Reporting of Malignant Odontogenic Tumors: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer ReportingPieter J Slootweg, Edward W Odell, Daniel Baumhoer, et al.
Wellcome Open Research|June 14, 2024
COVID-19 vaccine hesitancy in an ethnically diverse community: descriptive findings from the Born in Bradford studyJosie Dickerson, Bridget Lockyer, Rachael H Moss, et al.
Pageof 62